Company / SG&A Expense
Cogent Biosciences, Inc. SG&A Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$63.6M
FY2025
5-year range
$19.6M / $63.6M
FY2021-FY2025
Trend
+46.9%
vs FY2024
Sector context
#139 of 211
Health Care
What the data says
At $64M, Cogent Biosciences, Inc.'s sg&a expense ranks #73 of 211 in the Health Care sector. SG&A Expense has increased for 8 consecutive years, from $5M in FY2017 to $64M in FY2025.
Based on SEC 10-K filings.
$64M in FY2025 with a 5-year CAGR of +29.6%.
Increased from $34M to $64M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +34.4%
- 5-Year CAGR
- +29.6%
- 10-Year CAGR
- -
Sector benchmark
#73 of 211 in Health CareTop 34% of 211This company $63.6M Sector average $728.7M
▼
-91.3% below sector average
Key checks
Key Insights
- Cogent Biosciences, Inc.'s sg&a expense has grown for 8 consecutive years.
- 5-year CAGR of +29.6%, indicating consistent growth.
- In FY2025, sg&a expense increased 46.9% year-over-year.
- Ranks #139 out of 211 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $63.6M | +46.9% |
| FY2024 | $43.3M | +25.9% |
| FY2023 | $34.4M | +31.1% |
| FY2022 | $26.2M | +33.5% |
| FY2021 | $19.6M | +12.7% |
| FY2020 | $17.4M | +58.8% |
| FY2019 | $11.0M | +47.1% |
| FY2018 | $7.5M | +59.3% |
| FY2017 | $4.7M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026